Uses and compositions for treatment of psoriatic arthritis

• US 9,624,295 B2
• Filed: 04/10/2007
• Issued: 04/18/2017
• Est. Priority Date: 04/10/2006
• Status: Active Grant

• Current Assignee: AbbVie Biotechnology Ltd. (Puerto Rico) (Abbvie Incorporated)
• Original Assignee: AbbVie Biotechnology Ltd. (Puerto Rico) (Abbvie Incorporated)
• Inventors: Medich, John R., Wong, Robert L., Perdok, Renee J., Sasso, Eric H., Hoffman, Rebecca S., Mease, Phillip, Ritchlin, Christopher T.
• Primary Examiner(s): Shafer, Shulamith H
• Application Number:
  US11/786,459
• Publication Number:
  US 20090028794A1
• Time in Patent Office: 3,661 Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55 characterised by the host/recipient, e.g. newborn with maternal antibodies
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: G01N 2800/102 Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Abstract

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject.

Claims

1. A method of treating a subject having oligoarthritis with a tender joint count (TJC)<

5 or a swollen joint count (SJC)<

5, in association with psoriatic arthritis, the method comprising administering to the subject about 40 mg of adalimumab once subcutaneously every other week,

wherein at least an ACR20 response is achieved following a treatment period of at least about 12 weeks and the at least an ACR20 response is maintained following a treatment period of at least about 48 weeks,

thereby treating the subject having psoriatic arthritis with oligoarthritis in association with psoriatic arthritis.

2. The method of claim 1, wherein at least an ACR50 response achieved by the subject following a treatment period of about 12 weeks and the at least an ACR50 response is maintained following a treatment period of at least about 48 weeks.

3. The method of claim 1, wherein said treatment period is about 48 weeks.

4. The method of claim 2, wherein said treatment period is about 48 weeks.

5. The method of claim 1, wherein at least an ACR70 response is achieved by the subject following a treatment period of about 12 weeks and the at least an ACR 70 response is maintained following a treatment period of at least about 48 weeks.

6. The method of claim 5, wherein said treatment period is about 48 weeks.